PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms PRE-EMPT
- 17 Jul 2017 Planned End Date changed from 1 Sep 2019 to 30 Jun 2021.
- 11 Dec 2015 Accrual to date is 37% according to the United Kingdom Clinical Research Network record.
- 04 Nov 2015 Accrual to date is 19% according to the United Kingdom Clinical Research Network record.